Regeneron Pharmaceuticals said on Thursday that it expects to be excluded from a roster of drugmakers that could face new U.S. tariffs tied to unresolved pricing commitments.
Late on Wednesday, press reports indicated the Trump administration may unveil a slate of tariffs as soon as Thursday aimed at pharmaceutical firms that have not reached agreements to guarantee lower drug prices for U.S. consumers. Regeneron said it anticipates reaching a pact with the administration "in the near future" that would lower prescription drug prices for the government’s Medicaid program and for patients who pay cash.
Company officials highlighted that Regeneron remains the only company among 17 large pharmaceutical manufacturers that received letters from the president in July that has not yet signed a pricing agreement. The broader group of drugmakers that have made deals with the administration committed to a set of measures that include most-favoured-nation pricing, direct-to-consumer sales through a new government platform called TrumpRx.gov, and billions of dollars of U.S. investments.
Regeneron emphasized its expectation that a formal announcement will follow shortly, framed as a near-term agreement to reduce costs for specified patient groups. The company did not provide additional details on the timing or the precise terms beyond the focus on Medicaid beneficiaries and cash-paying patients.
Also noted in public commentary are commitments made by other participating drug manufacturers: adopting most-favoured-nation pricing, providing access via a government marketplace identified as TrumpRx.gov, and pledging substantial domestic investment. Those commitments form the basis of the administration’s approach to incentivize lower prices through agreements rather than broad-based tariffs, according to the reporting referenced by Regeneron.
Separately, automated equity-research services were cited as evaluating Regeneron alongside a wide swath of companies. One such service assesses firms monthly using numerous financial metrics to identify stocks with attractive risk-reward profiles, noting that it has highlighted past winners. The automated tool claims neutrality and purports to surface opportunities based on fundamentals, momentum, and valuation.
Regeneron’s statement underscores its expectation that it will not be included on any immediate tariff list, while signaling that a pricing agreement with the administration is forthcoming. The company did not enumerate further specifics or a definitive timeline for a formal signing.